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SYNTHETIC GROWTH HORMONE
RELEASERS DETECTED IN SEIZED
DRUGS: NEW TRENDS IN THE USE
OF DRUGS FOR PERFORMANCE
ENHANCEMENT
Gone are the days when gym users in search of drugs to
boost performance and muscular appearance resorted to
drug regimes of just oral and injectable versions of ana-
bolic steroids. Today, information gleaned from seizures
made by law enforcement agencies, personal anecdotes
and hearsay shared both in gyms and on the internet,
drug analysis reports, articles in newspapers and muscle
genre magazines and observation of illicit suppliers’ web-
sites reveals that a host of synthetic peptide hormones are
now available on the ‘life-style’ drug market [1]. These
include growth hormone releasers such as CJC-1295,
GHRP-2 and GHRP-6 [2–7]. These drugs have similar
effects on the body, mainly triggering the pulsatile releas-
ing activity of human growth hormone (hGH) from the
anterior pituitary gland [8]. This hormone, in turn, is
involved in the regulation of body composition, due to its
anabolic and lipolytic actions, as well as physical perfor-
mance and wellbeing [9].
Custom ofﬁcers at Copenhagen Airport (Denmark)
intercepted a package from China—shipped via
FedEx®—containing ﬁve identical cardboard boxes, each
holding 10 clear glass vials (Fig. 1). The vials were
handed over to the medicine regulatory authority in
Denmark (the Danish Health and Medicines Authority)
and given to us to examine for research purposes. None
of the vials were labelled, nothing was printed on the
cardboard boxes and there were no accompanying package
leaﬂets, giving the name of the drugs, strength and route of
administration. All vials in four of the boxes had orange-
coloured plastic caps; the vials in the remaining box had
blue caps. Otherwise, therewas noway to tell the vials
apart. A closer inspection revealed that the vials contained
a white lyophilized powder, presumably for the preparation
of solutions for injection. To identify the active substance(s),
we analysed the contents of one vial from each cardboard
box using high-performance tandem mass spectrometry.
Our analysis showed that four vials (with
orangecoloured caps) contained CJC-1295 and one vial
(with a blue cap) contained GHRP-2. We also found man-
nitol in the CJC-1295 preparation—a substance previously
detected in illicit drugs, where it is mixed in to add bulk
[10]. These ﬁndings add to reports of growth hormone
releasers found in illicit preparations in Europe [2–7] and
Australia [11], and suggest new drug-using trends.
The potential harms relating to the consumption of
growth hormone releasers for performance enhance-
ment are unknown. However, users are exposed to risks
from a broad range of defects discovered in illicit market
products, including unknowing exposure to undeclared
active substances, unknown amounts of active substance
and/or contamination [12–14]. The marketing of
growth hormone releasers as improved ways to increase
performance and appearance, compared with ‘old’ drugs
such as anabolic steroids, can be seen as a sign of the
increasing commodiﬁcation of ‘life-style’ drugs [15].
Further, the existence of global shipment options (includ-
ing well-established delivery services) that are cheap and
fast allows transnational distribution of illicit drugs, as
highlighted by this study.
Systematic intelligence-gathering concerning new
trends in substance use for performance enhancement
purposes and the harms it may cause is needed
urgently, especially as tailored public health responses are
limited. Health-care professionals encountering users
seeking treatment or health-related advice relating to
‘performance-enhancing drugs’ should be aware of the
variety of new drugs on the market.
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NEW ALCOHOL POLICIES APPEAR TO
HAVE REDUCED TRAFFIC CASUALTIES IN
CHILE
In 2012, Chile initiated action set out in its National
Alcohol Strategy published in March of 2010 [1]. In
the particular plan to reduce alcohol-related trafﬁc
casualties, there were three components were included.
First, the legal blood alcohol (BAC) limit was reduced
from 0.8 to 0.3mg, and penalties for exceeding this
were increased. Secondly, a strong and extensive press
and media campaign was launched. Thirdly, law
enforcement measures aimed at driver sobriety were
intensiﬁed, including providing police with portable
Alcotests and medical devices for immediate testing of
blood samples [2].
After the ﬁrst 2 years of implementation, the sobriety
rates reported by police increased from almost 65% to
almost 95%, and the national anual rate of alcohol-related
trafﬁc fatalities reduced by 28% (from the previous 10-year
average of 252 to 148 in 2012 and 2013) [3]. This height-
ened sobriety rate could have been due to an increase in
the number of random police checkpoints in 2012. How-
ever, the rate of sobriety remained constant throughout
the year, regardless of the variable intensity of police activ-
ity, which suggests that the policies described above may
have brought about change in the behaviour of Chilean
drivers.
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